Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$3.16B |
| 2 |
Merck
MRK
|
+$2.72B |
| 3 |
SLB Ltd
SLB
|
+$1.62B |
| 4 |
Target
TGT
|
+$1.6B |
| 5 |
General Mills
GIS
|
+$930M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.81B |
| 2 |
Blackrock
BLK
|
+$2.57B |
| 3 |
US Bancorp
USB
|
+$1.84B |
| 4 |
M&T Bank
MTB
|
+$808M |
| 5 |
Huntington Bancshares
HBAN
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.45% |
| 2 | Financials | 11.9% |
| 3 | Healthcare | 10.6% |
| 4 | Consumer Discretionary | 9.01% |
| 5 | Industrials | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3301
Microvast
MVST
$282M
| $131K | ﹤0.01% |
112,062
+1,291
| +1% | +$2.24K |
|
3302
United States Antimony
UAMY
$944M
| $130K | ﹤0.01% |
59,275
| – | – |
|
|
AVR
3303
Anteris Technologies
AVR
$799M
| $130K | ﹤0.01% |
+35,748
| New | +$230K |
|
3304
Sutro Biopharma
STRO
$426M
| $130K | ﹤0.01% |
19,990
-5,210
| -21% | -$82.1K |
|
3305
Flotek Industries
FTK
$1.29B
| $130K | ﹤0.01% |
15,583
+2
| +0% | +$17 |
|
|
KG
3306
Kestrel Group
KG
$71.1M
| $130K | ﹤0.01% |
11,358
| – | – |
|
3307
Century Therapeutics
IPSC
$361M
| $129K | ﹤0.01% |
270,820
-86,985
| -24% | -$65.4K |
|
3308
Acumen Pharmaceuticals
ABOS
$165M
| $129K | ﹤0.01% |
116,902
-9,845
| -8% | -$14.1K |
|
|
BRDG
3309
DELISTED
Bridge Investment Group
BRDG
| $128K | ﹤0.01% |
13,408
+2
| +0% | +$17 |
|
3310
Ispire Technology
ISPR
$97.6M
| $127K | ﹤0.01% |
46,503
| – | – |
|
3311
Quest Resource Holding
QRHC
$26.6M
| $126K | ﹤0.01% |
48,540
| – | – |
|
3312
Vera Bradley
VRA
$99.2M
| $125K | ﹤0.01% |
55,463
-11,087
| -17% | -$35.8K |
|
3313
ClearPoint Neuro
CLPT
$391M
| $123K | ﹤0.01% |
10,369
| – | – |
|
|
ATYR
3314
aTyr Pharma
ATYR
$50.5M
| $121K | ﹤0.01% |
39,911
+222
| +0.6% | +$809 |
|
|
VCSA
3315
DELISTED
Vacasa, Inc. Class A Common Stock
VCSA
| $120K | ﹤0.01% |
22,317
| – | – |
|
3316
Abeona Therapeutics
ABEO
$385M
| $116K | ﹤0.01% |
24,457
+607
| +3% | +$3.3K |
|
3317
CervoMed
CRVO
$26.3M
| $116K | ﹤0.01% |
12,722
| – | – |
|
3318
VirTra
VTSI
$34.4M
| $116K | ﹤0.01% |
28,501
| – | – |
|
3319
Gevo
GEVO
$382M
| $115K | ﹤0.01% |
99,561
| – | – |
|
|
ZYXI
3320
DELISTED
Zynex
ZYXI
| $115K | ﹤0.01% |
52,317
+8,661
| +20% | +$56.5K |
|
|
RDNW
3321
RideNow Group
RDNW
$254M
| $115K | ﹤0.01% |
40,804
| – | – |
|
3322
Jasper Therapeutics
JSPR
$21.9M
| $115K | ﹤0.01% |
26,648
-5,689
| -18% | -$37.9K |
|
|
AISP
3323
Airship AI Holdings
AISP
$66.8M
| $114K | ﹤0.01% |
29,507
| – | – |
|
3324
X4 Pharmaceuticals
XFOR
$392M
| $114K | ﹤0.01% |
16,051
+1,444
| +10% | +$19.9K |
|
|
BLUE
3325
DELISTED
bluebird bio
BLUE
| $113K | ﹤0.01% |
23,235
-4,417
| -16% | -$26.6K |
|
Similar funds
Charles Schwab's Q1 2025 Portfolio in Review
As of Q1 2025, Charles Schwab held 3,548 positions worth $533B, down 1.7% from $542B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 3.6%. Charles Schwab opened 55 new positions and exited 74, leaving the 3,548-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2025 buy was iShares Currency Hedged MSCI Eurozone ETF: 7,259,426 shares worth $283M.
- Charles Schwab added most to ConocoPhillips in Q1 2025, an estimated $3.16B increase.
- Charles Schwab's biggest Q1 2025 reduction was Pfizer, cutting an estimated $2.81B.
- Charles Schwab fully exited Brookfield in Q1 2025, selling an estimated $218M.
- Charles Schwab's ten largest holdings make up 20% of its $533B portfolio in Q1 2025.
- Charles Schwab opened 55 new positions and closed 74 in Q1 2025.
- Charles Schwab's portfolio value fell 1.7% quarter-over-quarter to $533B.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.